Herm Rosenman sold $11M of NTRA
director at Natera, Inc.. 48,419 shares at an average of $227.42, traded Dec 12, 2025, filed Dec 16, 2025.
Score components
- +15RoleDirector
- +25Trade size$11.0M at market
- +20Share of holdings soldSold 70% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.7%, 3m -12.8%, 6m -3.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001230057-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 31, 2025 | AGrant or award Common Stock | +132 | - | - | 68,761 | Dec 16, 2025 |
| Dec 12, 2025 | SOpen-market sale Common Stock | -14,372 | $226.62 | $3.3M | 54,389 | Dec 16, 2025 |
| Dec 12, 2025 | SOpen-market sale Common Stock | -21,910 | $227.35 | $5.0M | 32,479 | Dec 16, 2025 |
| Dec 12, 2025 | SOpen-market sale Common Stock | -11,987 | $228.49 | $2.7M | 20,492 | Dec 16, 2025 |
| Dec 12, 2025 | SOpen-market sale Common Stock | -150 | $229.10 | $34k | 20,342 | Dec 16, 2025 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 40Moderate | Natera, Inc. | John Fesko PRESIDENT, CHIEF BUS. OFFICER | $2.1M 6,517 shares | -3% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $2.0M 6,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.